FairJourney Biologics
António Parada has extensive work experience in the biotechnology and healthcare sector. António is currently the Chief Executive Officer at FairJourney Biologics since May 2012. Prior to this, they served as the Chairman of the Supervisory Board at EMBLEM since January 2011. António also held the position of Board Member at Centro de Diagnóstico y Estudios Metabólicos Avanzados de Cantabria (CDEMAC) from May 2014 to May 2017. Additionally, they served as a Member of the External Advisory Board at ERA-NET infecta from January 2013 to November 2016. From June 2002 to September 2013, they were the General Manager at IBMC - Instituto de Biologia Molecular e Celular. António also served as the Manager of the Clinical Trials Unit at IPO Porto from February 2011 to May 2012. Earlier in their career, they held various roles including Site Manager at Ablynx from June 2008 to March 2012, CEO at BioCodex from June 2002 to December 2008, and Board Member at Bioteca, S.A. and Genetest from 2005 to 2008 and 2004 to 2008 respectively.
António Parada pursued their education at the Faculdade de Ciências da Universidade do Porto from 1987 to 1993, majoring in Botany/Plant Biology. Later, in 2000 and 2001, they attended the Universidade Católica do Porto, where they obtained an MBA degree.
This person is not in any offices
FairJourney Biologics
FairJourney Biologics is a privately established company with an outstanding track record of biotech and biopharmaceutical partners (Merus, argenX, BMS, Bayer, among others), offering a range of assets and services on antibody discovery, engineering, production, characterization up to cell line development stages. Our naïve and immune libraries from humans, rodents and llama, together with our know-how and internal technological development allow us to contribute to the pipeline of our partners on complex targets, leading to 14 known antibodies in the clinic. More recently, FairJourney Biologics has been joined by specialists in the field such as Tariq Ghayur (formerly Abbvie) and Rene Hoet (formerly Bayer), creating a panel of available scientists as service to support complex antibody projects. From target validation up to cell line development and pre-CMC reporting, FairJourney Biologics is a one stop shop leader in antibody services. As of 2022, the company has a headcount of above 200 staff members and a track record of more than 800 projects on a variety of areas.